《Table 1A comparison of the conventional drug discovery and development process with those of the CA
CD19 is ubiquitously expressed on all stages of B cells except for hematopoietic stem cells(HSCs)and certain plasma cells.It is also expressed on most B lineage leukemia and lymphoma cells[51,55].It is expected that a successful adoptive CART19 transfer will eliminate B lineage malignancies and normal B cells leading to B cell aplasia.As the treatment does not eradicate the vital HSC,and as B cell aplasia is treatable with intravenous immunoglobulin replacement,CD19 is an excellent target for eliminating B lineage malignancies via the adoptive transfer of CAR T cells due to its antibody accessibility,tumor specificity,and non-lethal normal organ tissue distribution[46,56].
图表编号 | XD0061017800 严禁用于非法目的 |
---|---|
绘制时间 | 2019.02.01 |
作者 | Fang Chen、Joseph A.Fraietta、Carl H.June、许中伟、J.Joseph Melenhorst、Simon F.Lacey |
绘制单位 | Department of Pathology and Laboratory Medicine,University of Pennsylvania、Center for Cellular Immunotherapies,University of Pennsylvania、Department of Pathology and Laboratory Medicine,University of Pennsylvania、Center for Cellular Immunotherapies,Univer |
更多格式 | 高清、无水印(增值服务) |